申请人:NANJING SANHOME PHARMACEUTICAL CO., LTD.
公开号:US20200165265A1
公开(公告)日:2020-05-28
Disclosed are a class of compounds which are inhibitors of acetyl-CoA carboxylase (ACC) and the use thereof. In particular, provided are compounds as shown in formula I or isomers, pharmaceutically acceptable salts, solvates, crystals or prodrugs thereof, and methods for preparing the same, and pharmaceutical compositions comprising the compounds and the use of the compounds or compositions for treating and/or preventing diseases associated with ACC expression, such as fibrotic diseases, metabolic diseases, cancers or tissue hyperplasia diseases. The compound has a good inhibitory activity against ACC and shows good promise to be a therapeutic drug for fibrotic diseases, metabolic diseases, cancers or tissue hyperplasia diseases.
公开了一类化合物,这些化合物是乙酰辅酶A羧化酶(ACC)的抑制剂及其用途。具体地,提供了如公式I所示的化合物或其异构体,药学上可接受的盐、溶剂合物、晶体或前药,以及制备这些化合物的方法,以及包含这些化合物的药物组合物和用于治疗和/或预防与ACC表达相关的疾病的化合物或组合物的用途,如纤维化疾病、代谢性疾病、癌症或组织增生疾病。该化合物对ACC具有良好的抑制活性,并显示出成为治疗纤维化疾病、代谢性疾病、癌症或组织增生疾病的治疗药物的良好前景。